- ROME, 09 NOV - An anti-Covid vaccine developed jointly by Pfizer and Biontech was found to be effective in preventing 90 percent of infections during phase 3 of the trial, which is still ongoing.
This was announced by Pfizer president Albert Bourla.
The German Biontech then confirmed the announcement by adding in a publication that it wanted to ask the American FDA for authorization for the production, together with Pfizer itself, next week.
"Great news from Pfizer and Biontech about the positive results of their clinical trial for a Covid-19 vaccine. European science works! The Commission will soon sign a contract with them for up to 300 million doses. We continue to protect each other in the meantime." the comment of the president of the European Commission, Ursula von der Leyen in tweets, while the director of the WHO, Tedros Adhanom Ghebreyesus, called the announcement on the vaccine "encouraging".